These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Immunotherapeutic Potential of Interleukin-32 and Trained Immunity for Leishmaniasis Treatment. Teufel LU; Joosten LAB; Dos Santos JC Trends Parasitol; 2021 Feb; 37(2):130-141. PubMed ID: 33082090 [TBL] [Abstract][Full Text] [Related]
29. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Convit J; Castellanos PL; Rondon A; Pinardi ME; Ulrich M; Castes M; Bloom B; Garcia L Lancet; 1987 Feb; 1(8530):401-5. PubMed ID: 2880213 [TBL] [Abstract][Full Text] [Related]
30. A historical review of the role of cytokines involved in leishmaniasis. Mirzaei A; Maleki M; Masoumi E; Maspi N Cytokine; 2021 Sep; 145():155297. PubMed ID: 32972825 [TBL] [Abstract][Full Text] [Related]
31. Possibilities and challenges for developing a successful vaccine for leishmaniasis. Srivastava S; Shankar P; Mishra J; Singh S Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732 [TBL] [Abstract][Full Text] [Related]
32. Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against Seyed N; Peters NC; Rafati S Front Immunol; 2018; 9():1227. PubMed ID: 29922288 [TBL] [Abstract][Full Text] [Related]
33. Chemokines in host-parasite interactions in leishmaniasis. Teixeira MJ; Teixeira CR; Andrade BB; Barral-Netto M; Barral A Trends Parasitol; 2006 Jan; 22(1):32-40. PubMed ID: 16310413 [TBL] [Abstract][Full Text] [Related]
34. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Cabrera M; Blackwell JM; Castes M; Trujillo D; Convit J; Shaw MA Parasite Immunol; 2000 Feb; 22(2):73-9. PubMed ID: 10652119 [TBL] [Abstract][Full Text] [Related]
35. Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development. Volpedo G; Pacheco-Fernandez T; Bhattacharya P; Oljuskin T; Dey R; Gannavaram S; Satoskar AR; Nakhasi HL Front Immunol; 2021; 12():748325. PubMed ID: 34712235 [TBL] [Abstract][Full Text] [Related]
36. Recent updates and perspectives on leishmaniasis. Savoia D J Infect Dev Ctries; 2015 Jul; 9(6):588-96. PubMed ID: 26142667 [TBL] [Abstract][Full Text] [Related]
37. Leishmaniasis in humans: drug or vaccine therapy? Ghorbani M; Farhoudi R Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800 [TBL] [Abstract][Full Text] [Related]
38. Vaccine candidates for leishmaniasis: a review. Nagill R; Kaur S Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175 [TBL] [Abstract][Full Text] [Related]
39. Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease. Roatt BM; Aguiar-Soares RD; Coura-Vital W; Ker HG; Moreira Nd; Vitoriano-Souza J; Giunchetti RC; Carneiro CM; Reis AB Front Immunol; 2014; 5():272. PubMed ID: 24982655 [TBL] [Abstract][Full Text] [Related]
40. Immunomodulation by chemotherapeutic agents against Leishmaniasis. Saha P; Mukhopadhyay D; Chatterjee M Int Immunopharmacol; 2011 Nov; 11(11):1668-79. PubMed ID: 21875692 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]